WBO:HPHA (Germany)
Â
Akt. nach Kapitalherabsetzung
€
2.55
(0%)
Jul 15
Business Description
Heidelberg Pharma AG
ISIN : DE000A11QVV0
Share Class Description:
WBO:HPHA: Akt. nach KapitalherabsetzungTotal Employee Number:
66Description
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 120.27 | |||||
Equity-to-Asset | -0.49 | |||||
Debt-to-Equity | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -19.2 | |||||
Beneish M-Score | -5.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -60.3 | |||||
3-Year EBITDA Growth Rate | -23.7 | |||||
3-Year EPS without NRI Growth Rate | -19.7 | |||||
3-Year FCF Growth Rate | -38.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.32 | |||||
9-Day RSI | 35.85 | |||||
14-Day RSI | 39.02 | |||||
3-1 Month Momentum % | -7.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.4 | |||||
Quick Ratio | 1.33 | |||||
Cash Ratio | 1.03 | |||||
Days Inventory | 7285.84 | |||||
Days Sales Outstanding | 5.92 | |||||
Days Payable | 3293.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 0.04 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 81.27 | |||||
Operating Margin % | -1389.31 | |||||
Net Margin % | -1261.85 | |||||
EBITDA Margin % | -1146.29 | |||||
FCF Margin % | -334.02 | |||||
OCF Margin % | -333.12 | |||||
ROE % | -724.36 | |||||
ROA % | -85.25 | |||||
ROIC % | -203.77 | |||||
3-Year ROIIC % | 152.03 | |||||
ROC (Joel Greenblatt) % | -520.8 | |||||
ROCE % | -99.38 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 37.51 | |||||
EV-to-EBIT | -2.38 | |||||
EV-to-EBITDA | -2.56 | |||||
EV-to-Revenue | 29.33 | |||||
EV-to-FCF | -3.94 | |||||
Price-to-GF-Value | 2.71 | |||||
Price-to-Median-PS-Value | 1.96 | |||||
Earnings Yield (Greenblatt) % | -41.95 | |||||
FCF Yield % | -24.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Heidelberg Pharma AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 7.445 | ||
| EPS (TTM) (€) | -0.711 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 39.02 | ||
| 14-Day ATR (€) | 0.054295 | ||
| 20-Day SMA (€) | 2.617 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.52 - 2.84 | ||
| Shares Outstanding (Mil) | 46.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Heidelberg Pharma AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Heidelberg Pharma AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-15 08:00 | In 92 days | ||
| Third quarter earnings results for 2026 | 2026-10-15 | In 91 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-15 08:00 | 2.55 (-4.14%) | ||
| Second quarter earnings results for 2026 | 2026-07-15 | 2.55 (-4.14%) | ||
| General meeting for 2026 | 2026-06-23 09:00 | 2.62 (+1.55%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:00 | 2.79 (+0.72%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 2.79 (+0.72%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-26 14:00 | -- | ||
| Annual report for 2025 | 2026-03-26 08:00 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | -- |
Show
Entries
Heidelberg Pharma AG Frequently Asked Questions
What is Heidelberg Pharma AG(WBO:HPHA)'s stock price today?
The current price of WBO:HPHA is €2.55. The 52 week high of WBO:HPHA is €2.84 and 52 week low is €2.52.
When is next earnings date of Heidelberg Pharma AG(WBO:HPHA)?
The next earnings date of Heidelberg Pharma AG(WBO:HPHA) is 2026-07-15.
Does Heidelberg Pharma AG(WBO:HPHA) pay dividends? If so, how much?
Heidelberg Pharma AG(WBO:HPHA) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Heidelberg Pharma and Huadong Announce Strategic Partnership, Including Equity Investment | 2022-02-28 |
Articles on Heidelberg Pharma AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers